interferon
ifn
first
discov
base
observ
cell
challeng
heatinactiv
influenza
viru
secret
macromolecul
abl
interfer
sever
virus
infecti
influenza
viru
vaccinia
viru
studi
followup
research
led
develop
ifn
therapeut
tool
treat
number
infecti
diseas
particular
chronic
hepat
b
hepat
c
ifn
elicit
antivir
action
induc
wide
array
ifnstimul
gene
isg
interact
specif
receptor
ifn
activ
signal
transduc
activ
transcript
stat
complex
phosphoryl
stat
activ
classic
janu
kinasestat
signal
pathway
initi
transcript
differ
isg
mechan
isg
particip
ifnmedi
respons
hepat
b
viru
hbv
hepat
c
viru
hcv
fulli
understood
previou
studi
demonstr
ifn
inhibit
hbv
replic
multipl
step
life
cycl
deamin
degrad
viral
transcript
templat
coval
close
circular
dna
cccdna
apolipoprotein
b
mrna
edit
enzym
catalyt
subunit
silenc
cccdna
epigenet
regul
stat
complex
downregul
viral
mrna
stabil
antivir
zinc
finger
protein
inhibit
viral
pregenom
rna
encapsid
via
myxoma
resist
protein
reduc
virion
secret
tetherin
ifn
also
promot
viral
nucleocapsid
degrad
hcv
host
isg
show
much
complex
interact
exampl
cellular
pattern
recognit
receptor
detect
molecular
pattern
hcv
therebi
form
posit
feedback
loop
amplifi
ifn
signal
mani
isg
report
inhibit
hcv
rna
replic
viral
protein
translat
either
directli
indirectli
includ
rnaspecif
adenosin
deaminas
viperin
synthetas
ifn
also
induc
transmembran
protein
report
inhibit
hcv
entri
viru
entri
multistep
process
viru
first
attach
cell
type
unspecif
molecul
bind
specif
receptor
enter
cell
heparan
sulfat
present
surfac
extracellular
matrix
mammalian
cell
serv
attach
factor
anchor
number
envelop
virus
herp
simplex
viru
respiratori
syncyti
viru
human
immunodefici
viru
cytomegaloviru
dengu
viru
hbv
hcv
well
nonenvelop
virus
human
papillomaviru
footandmouth
diseas
viru
although
influenc
isg
product
replic
hbv
hcv
studi
extens
littl
known
influenc
ifn
treatment
earli
step
viru
life
cycl
investig
whether
abl
induc
solubl
factor
would
extracellular
antivir
activ
studi
reveal
novel
antivir
mechan
upon
treatment
factor
secret
bind
heparan
attach
receptor
mani
virus
includ
hbv
lead
inhibit
viru
attach
block
infect
heparg
cell
cultur
william
e
medium
gibco
carlsbad
usa
supplement
fetal
calf
serum
fetalclon
ii
hyclon
littl
chalfont
unit
kingdom
mm
lglutamin
gibco
carlsbad
usa
uml
penicillinstreptomycin
gibco
carlsbad
usa
gentamicin
ratiopharm
ulm
germani
ieml
human
insulin
sanofiaventi
pari
franc
hydrocortison
pfizer
carlisl
usa
describ
cell
cultur
maintain
atmospher
infect
cell
maintain
week
standard
medium
differenti
week
medium
supplement
dmso
sigma
munich
germani
hbv
concentr
supernat
cell
use
centrifug
filter
devic
centricon
biomax
millipor
corp
bedford
quantifi
hbvdna
qpcr
immedi
collect
viru
stock
divid
aliquot
store
use
inocul
differenti
heparg
cell
perform
multipl
infect
genom
copi
per
cell
differenti
medium
contain
peg
sigma
munich
germani
h
end
incub
period
cell
wash
three
time
pb
cultur
differenti
medium
hbsag
measur
use
axsym
system
abbott
chicago
usa
hbeag
measur
bep
iii
system
siemen
munich
germani
total
cellular
dna
dna
cell
cultur
supernat
extract
infect
cell
use
nucleospin
tissu
kit
machereynagel
germani
realtim
quantit
pcr
qpcr
perform
use
system
roch
manheim
germani
hbvdna
cccdna
detect
use
specif
pcr
primer
tabl
hbvdna
cell
cultur
supernat
quantifi
rel
extern
plasmid
standard
intracellular
hbvdna
cccdna
express
normal
ratio
genom
singl
copi
gene
prion
protein
prnp
lysat
heparg
cell
obtain
ad
mper
mammalian
protein
extract
reagent
thermo
scientif
schwert
germani
onto
cell
per
well
incub
five
minut
ld
sampl
buffer
nonreduc
ad
sampl
shaken
five
minut
rpm
protein
separ
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
protein
blot
onto
pvdf
membran
membran
block
milk
one
hour
room
temperatur
follow
overnight
incub
polyclon
rabbit
antihbv
core
antibodi
gift
heinz
schaller
plate
coat
heparin
solut
per
well
incub
overnight
well
wash
time
pb
sampl
ad
plate
incub
overnight
sampl
aspir
plate
wash
time
pb
block
buffer
bsa
solut
pbst
ad
well
incub
h
plate
wash
time
pbst
block
buffer
viru
stock
solut
murex
conjug
solut
murex
hbsag
version
kit
saluggia
itali
ad
per
well
plate
incub
h
follow
time
pbst
wash
substrat
solut
ad
per
well
h
incub
stop
solut
ad
per
well
light
absorpt
measur
nm
nm
refer
wavelength
infinit
tecan
switzerland
sampl
treat
uml
nglycosidas
f
bead
edm
millipor
bedford
overnight
trypsin
gibco
carlsbad
usa
hour
proteinas
k
hour
incub
mm
proteas
inhibitor
pefabloc
sigma
munich
germani
ad
sampl
final
sampl
purifi
vivaspin
mwco
spincolumn
gelifesci
freiburg
germani
cell
electropor
report
construct
describ
previous
cultur
supernat
transfect
cell
harvest
filter
filter
unit
millipor
germani
precipit
overnight
viru
pellet
centrifug
h
resuspend
dmem
store
use
prepar
titrat
infect
limit
dilut
assay
cell
tissu
cultur
infect
dose
calcul
base
method
describ
cell
seed
plate
h
prior
hcv
inocul
moicel
hcv
luciferas
viru
use
infect
cell
h
prepar
elut
concentr
present
cultur
medium
whole
process
hcv
infect
luciferas
assay
perform
use
assay
kit
promega
usa
follow
manufactur
instruct
luminesc
measur
program
injectthenread
mode
infinit
switzerland
luciferas
assay
perform
triplic
student
unpair
twotail
ttest
perform
graphpad
prism
graphpad
softwar
la
jolla
ca
usa
data
mean
sd
twosid
p
valu
consid
signific
first
sought
investig
whether
pretreat
heparg
cell
ifna
infect
hbv
would
effect
establish
hbv
infect
figur
pretreat
result
declin
hbeag
hbsag
day
upon
hbv
infect
figur
b
c
concomitantli
intracellular
hbv
replic
marker
day
analyz
qpcr
analysi
reveal
reduct
cccdna
intracellular
hbvdna
pretreat
figur
western
blot
analysi
show
declin
intracellular
hbv
core
protein
product
figur
e
result
suggest
pretreat
cell
hour
suffici
induc
antivir
effect
ifninduc
antivir
factor
sustain
activ
infect
result
also
impli
induc
antivir
program
prevent
hbv
earli
infect
order
determin
whether
induc
antivir
program
would
prevent
initi
hbv
replic
inhibit
attach
entri
host
cell
condit
medium
prepar
treat
cell
figur
medium
contain
isg
product
isg
collect
ad
togeth
hbv
differenti
heparg
cell
compar
untreat
cell
isg
medium
treat
cell
show
decreas
cccdna
intracellular
hbvdna
demonstr
inhibitori
effect
isg
medium
figur
b
isg
medium
effect
appli
cell
alreadi
infect
figur
c
exclud
antivir
action
elicit
isg
medium
due
residu
neutral
antibodi
appli
either
isg
medium
ad
concomitantli
hbv
inoculum
hbv
infect
inhibit
effect
isg
medium
neutral
figur
prove
antivir
activ
isg
medium
elicit
residu
taken
togeth
experi
show
isg
medium
decreas
hbv
infect
cell
treat
hbv
infect
wherea
effect
observ
cell
treat
follow
hbv
infect
thu
conclud
treatment
induc
hepatoma
cell
secret
solubl
factor
solubl
factor
inhibit
hbv
infect
target
earli
step
hbv
infect
like
viru
entri
character
effect
interferon
induc
factor
perform
viru
attach
assay
figur
differenti
heparg
cell
incub
mock
untreat
differenti
heparg
cell
cultur
supernat
isg
medium
heatinactiv
isg
medium
isg
inactiv
synthet
antilipopolysaccharid
peptid
serv
posit
control
shown
inhibit
bind
step
mani
envelop
virus
includ
hbv
cell
inocul
viru
particl
hour
low
temperatur
prohibit
hbv
entri
host
cell
herebi
found
interferon
induc
solubl
factor
could
inhibit
hbv
bind
effici
heat
inactiv
led
attenu
antivir
effect
figur
b
result
demonstr
hbv
bind
host
cell
imped
treatment
isg
medium
contain
interferon
induc
solubl
factor
therefor
specul
induc
antivir
protein
associ
viru
one
essenti
viral
attach
factor
receptor
experiment
evid
present
hbv
initi
infect
hepatocyt
bind
heparan
sulfat
proteoglycan
therefor
analyz
whether
induc
factor
interrupt
interact
hbv
heparin
close
homologu
liver
heparin
sulfat
appli
cell
cultur
supernat
untreat
differenti
heparg
cell
isg
medium
heparin
column
analyz
residu
bind
capac
hbv
figur
hbv
virion
effici
bound
heparinsepharos
physiolog
salt
condit
mock
could
elut
use
high
salt
concentr
figur
b
hbv
particl
bind
heparin
reduc
particl
load
isg
medium
herebi
isg
medium
inhibit
hbv
bind
heparin
column
almost
effici
describ
previous
result
demonstr
isg
medium
compet
hbv
bind
heparin
investig
hypothesi
solubl
factor
isg
medium
competit
bind
heparin
cultur
cell
isg
medium
appli
heparin
column
flowthrough
low
heparin
affin
part
elut
high
heparin
affin
part
collect
appli
differenti
heparg
cell
figur
elut
fraction
heparin
column
contain
high
heparin
affin
factor
led
reduct
hbv
bind
heparg
cell
flowthrough
fraction
show
signific
inhibit
figur
b
conclus
result
show
interferon
induc
factor
inhibit
initi
bind
hbv
cell
surfac
direct
interact
heparan
sulfat
order
character
activ
factor
isg
medium
detail
determin
size
use
size
exclus
chromatographi
heparin
bind
fraction
purifi
appli
size
exclus
column
cutoff
kda
kda
kda
respect
concentr
separ
fraction
protein
size
figur
flowthrough
concentr
column
collect
six
differ
fraction
contain
differ
size
rang
protein
figur
b
incub
differenti
heparg
cell
hbv
inocul
elut
heparin
column
inhibit
hbv
replic
expect
among
differ
fraction
three
concentr
contain
protein
bigger
kda
show
antivir
effect
three
flowthrough
fraction
contain
protein
smaller
kda
reduc
infect
figur
c
confirm
bind
specif
induc
factor
heparin
coat
plate
heparin
ad
elut
heparin
column
differ
fraction
protein
concentr
column
determin
amount
hbv
could
still
bind
heparin
plate
figur
elut
fraction
respect
concentr
size
exclus
chromatographi
column
compet
hbv
bind
heparin
three
flowthrough
sampl
show
inhibit
hbv
bind
taken
togeth
suggest
interferon
induc
secret
factor
inhibit
bind
hbv
heparin
larger
kda
character
induc
bind
inhibitor
treat
heparin
column
purifi
isg
medium
elut
glycosidas
trypsin
proteinas
k
figur
e
interestingli
three
enzym
treatment
enhanc
hbv
replic
indic
antivir
factor
present
isg
medium
glycoprotein
strong
inhibitori
effect
glycosidas
factor
suggest
carbohydr
group
glycoprotein
might
play
import
role
interact
heparan
sulfat
hcv
altern
hepatotrop
viru
use
heparan
sulfat
primari
dock
site
infect
investig
whether
ifninduc
secret
factor
abl
also
inhibit
hcv
infect
heparin
column
elut
concentr
kda
protein
concentr
column
ad
infect
hcv
luciferas
viru
figur
importantli
elut
fraction
heparin
column
concentr
size
exclus
column
also
restrict
hcv
infect
figur
result
confirm
ifn
induc
secret
factor
block
hcv
bind
heparin
sulfat
proteoglycan
thu
abl
block
common
step
two
hepatotrop
virus
hbv
hcv
present
studi
describ
novel
antivir
mechan
target
hbv
hcv
bind
step
supernat
treat
cell
cultur
restrict
hbv
hcv
entri
infect
inhibit
contribut
one
secret
interferon
induc
protein
bind
heparin
column
result
indic
protein
treat
cell
cultur
supernat
bind
heparan
unspecif
attach
receptor
mani
virus
although
isg
medium
prepar
treat
cell
antivir
activ
isg
medium
unlik
due
residu
amount
present
condit
medium
de
novo
synthes
isg
medium
treat
cell
first
residu
would
fast
endocytos
rapidli
degrad
isg
produc
cell
second
treatment
induc
product
initi
interact
envelop
viru
host
cell
normal
mediat
membran
glycoprotein
bind
glycolipid
andor
glycoprotein
attach
factor
heparan
sulfat
proteoglycan
target
cell
surfac
hbv
first
encount
initi
via
interact
determin
heparan
sulfat
proteoglycan
result
larg
envelop
protein
abl
bind
specif
receptor
sodiumtaurochol
cotransport
polypeptid
allow
viral
entri
enzym
digest
experi
suggest
induc
glycoprotein
could
compet
viral
membran
protein
bind
heparin
sulfat
proteoglycan
thu
block
whole
entri
process
viru
infect
induc
antivir
respons
known
multifunct
long
time
howev
effect
viru
bind
entri
step
well
studi
recent
interferoninduc
transmembran
ifitm
protein
famili
shown
block
earli
stage
viral
infect
ifitm
origin
identifi
rnai
genet
screen
shown
inhibit
infect
vesicular
stomat
viru
vsv
influenza
viru
west
nile
viru
dengu
viru
later
ifitm
protein
found
potent
restrict
entri
infect
number
highli
pathogen
virus
includ
human
immunodefici
viru
hiv
filovirus
hcv
sar
coronaviru
recent
research
identifi
broad
antivir
isg
convert
cholesterol
solubl
antivir
factor
treatment
cultur
cell
inhibit
growth
broad
group
envelop
virus
includ
vsv
hiv
herp
simplex
viru
interestingli
also
block
hbv
entri
sinc
molecular
weight
ifitm
less
kda
factor
may
contribut
antivir
effect
observ
specif
inhibit
viru
entri
attract
therapeut
target
acut
also
chronic
viral
infect
case
chronic
infect
entri
inhibit
prohibit
infect
spread
naiv
cell
togeth
antivir
therapi
elimin
infect
cell
provid
higher
chanc
cure
exampl
hiv
infect
accomplish
interfer
viru
entri
use
protein
deriv
peptid
enfuvirtid
prevent
fusion
viru
host
cellular
membran
viru
entri
inhibit
also
provid
opportun
prevent
recurr
hepat
b
liver
transplant
previou
studi
demonstr
acyl
hbv
presderiv
lipopeptid
target
viral
envelop
protein
compon
could
prevent
interact
hbv
cellular
receptor
thu
prevent
de
novo
hbv
infect
human
mice
sinc
hepat
delta
viru
use
receptor
hbv
hbv
entri
inhibitor
equal
effect
virus
although
evid
indic
hbv
propag
celltocel
transmiss
numer
envelop
virus
shown
employ
mode
spread
involv
direct
cellcel
transmiss
releas
progeni
virus
extracellular
space
studi
show
myristoyl
presderiv
peptid
myrcludexb
could
block
hbv
celltocel
dissemin
among
human
hepatocyt
liver
human
mice
similarli
context
hcv
infect
entri
inhibitor
target
viral
receptor
use
monotherapi
shown
cure
chronic
infect
infect
human
mice
altogeth
recent
studi
result
indic
inhibit
hbvhcv
entri
bind
combin
establish
therapi
might
potenti
applic
prevent
vertic
transmiss
birth
reinfect
liver
transplant
chronic
hbv
infect
hbv
hcv
infect
hepatocyt
turnov
like
result
reduc
infect
even
importantli
recent
clinic
trial
use
entri
inhibitor
myrcludexb
treat
patient
chronic
hepat
delta
demonstr
entri
inhibitor
alon
combin
pronounc
antivir
effect
block
reinfect
protect
uninfect
hepatocyt
de
novo
infect
ifninduc
viral
entri
inhibitor
complement
alreadi
known
antivir
effect
identif
may
open
perspect
novel
therapeut
approach
hbv
hcv
infect
conclus
studi
reveal
abl
induc
solubl
factor
bind
heparan
glycosaminoglycan
lead
inhibit
hbv
hcv
bind
thu
unravel
novel
antivir
mechan
action
interferon
